Alliance for Pandemic Preparedness
June 15, 2021
SARS-CoV-2 Delta VOC in Scotland: Demographics, Risk of Hospital Admission, and Vaccine Effectiveness
Category: Article Summary
Topic: Vaccines and Immunity
Keywords (Tags): clinical characteristics, variant
- SARS-CoV-2 infections caused by the B.1.617.2 (Delta) variant of concern were at increased risk of hospitalization (HR=1.9) compared to the B.1.1.7 (Alpha) variant after adjusting for demographics, temporal trends, and comorbidities, according to an analysis of 19,543 confirmed infections and 377 hospitalizations in Scotland from April 1 to June 6, 2021. Considering the whole population cohort, estimated vaccine effectiveness 14 days after the second dose against infection was reduced against B.1.617.2 (Delta) compared to B.1.1.7 (Alpha) for the Pfizer-BioNTech (92% vs 79%) and Oxford-AstraZeneca vaccine (73% vs 60%).
Sheikh et al. (June 15, 2021). SARS-CoV-2 Delta VOC in Scotland: Demographics, Risk of Hospital Admission, and Vaccine Effectiveness. The Lancet. https://doi.org/10.1016/S0140-6736(21)01358-1